Optimizing MOAs of JAK Inhibitors in a 36-Year-Old Male With a History of Atopic Dermatitis
August 20th 2024Jayme Heim, MSN, FNP-BC, explores strategies for optimizing the mechanisms of action of topical JAK inhibitors in treating a 36-year-old male patient with a history of atopic dermatitis, highlighting the potential benefits and considerations of this therapeutic approach.
When to Discontinue Treatment: Interpreting Safety Signals and Adverse Event Patterns
August 8th 2024Key opinion leaders examine safety concerns and adverse event trends in psoriasis treatments, discussing how these factors influence decisions to discontinue therapy and transition patients to alternative interventions.